Vimta Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 6.6 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vimta Labs reported Q2 FY26 revenue from operations of Rs 101.85 crore, up about 20% from Rs 84.74 crore in Q2 FY25. Half-year revenue rose nearly 25% to Rs 199.41 crore versus Rs 159.62 crore a year ago. Profit after tax from continuing operations for the quarter stood at Rs 19.91 crore, up about 30% YoY, while H1 PAT grew around 41% to Rs 38.81 crore. The auditor (Gattamaneni & Co.) issued an unmodified limited review report with no qualifications. Operating cash flow for H1 FY26 was strongly positive at Rs 74.87 crore, and cash balances rose to Rs 28.14 crore from Rs 15.84 crore at the start of the year. The company also completed a 1:1 bonus issue in June 2025 and continues to record ESOP and PPP-related (FSSAI lab at JNPT) items.
Strong double-digit revenue and profit growth, clean auditor report, and healthy cash generation are positive signals for shareholders. The growth is from continuing operations (contract research and testing services) after the diagnostic business was hived off to Thyrocare, so the comparison is on a like-for-like basis and reflects genuine core-business momentum.